Tensive

Margherita Tamplenizza, Co-founder e Chief Quality Regulatory Affairs Officer di Tensive, e Diana Saraceni, Managing Partner di Panakès Partners e membro del Board di Tensive, saranno presenti ad “INVESTING FOR LIFE – Dall’Italia all’Europa i finanziamenti per la ricerca e l’innovazione nelle scienze della vita”, evento promosso da Cluster Nazionale Scienze della Vita ALISEI e Cluster lombardo scienze della vita che si terrà il 2–3 dicembre 2025.

📌 2 dicembre, 14:50–15:30
Margherita Tamplenizza parteciperà, in qualità di relatrice, nella tavola rotonda “Horizon: potenziare l’accesso dell’Italia ai finanziamenti UE”.

📌 2 dicembre, 17:10–17:50
Diana Saraceni farà parte del panel “Innovare per la vita: strumenti e strategie nazionali per la ricerca, l’innovazione e lo sviluppo”.

Per maggiori informazioni: clusteralisei.it/eventi/investing-for-life

It’s important during hashtag to raise awareness of the goals we are still striving to reach. Did you know that compared with mastectomy, more than twice as many patients undergo lumpectomy every year – and three-quarters of them receive no reconstruction care at all?

It’s not because there’s no need: up to 40% of patients report asymmetry or disfigurement that requires correction after lumpectomy, while many more simply tolerate these changes, even though they can be psychologically devastating. Rather, the reason these patients are untreated is that there simply is no viable reconstruction option for them.

That’s why Tensive is developing REGENERA™ and SOFTAG™ bioresorbable implants as minimally invasive, one-step solutions that are appropriate for any lumpectomy. Our implants use a soft synthetic scaffold that resembles a very fine sponge, whose structure facilitates regrowth of blood vessels and soft tissue, and which is gradually absorbed by the body. The devices are implanted during the lumpectomy procedure.

Imaging data from a first-in-human study and interim results from our ongoing pivotal trial confirm that breast restoration with REGENERA™ is safe and results in natural tissue that preserves the original shape and feel of the breast, yet is clearly differentiated from surrounding tissues on imaging.

SOFTAG™ uses the same bioresorbable, customizable scaffold as a tumor resection marker to support precision delivery of radiotherapy to the tumor bed.

Visit our website at www.tensive.com to learn more about our work to bring REGENERA™ and SOFTAG™ to approval for women undergoing lumpectomy.

Want to join a fast-growing company making a real impact? At Tensive, we’re on a mission to improve the quality of life for breast cancer patients after lumpectomy.

We’re looking for a passionate Quality Assurance Specialist to help bring our innovative solution to the market.

Check out the role here: https://www.tensivemed.com/it/careers/quality-assurance-specialist/

Let’s transform lives together!

Quality Assurance Specialist (Open) | Tensive We are looking for a Regulatory Affairs Specialist (RAS) to work closely with our Quality Assurance & Regulatory Affairs (QA&RA) team in managing the regulatory affairs activities and executing our Quality Management System (QMS) in accordance with the requirements of ISO 13485:2016.

In honor of Breast Cancer Awareness Month, we are excited to announce a significant milestone in our mission to support patients affected by breast cancer by improving their quality of life. Tensive has launched a pivotal clinical trial to assess the safety and performance of REGENERA in patients undergoing reconstructive surgery following lumpectomy for malignant breast lesions.

This study is a critical step in advancing innovative solutions for breast cancer patients, and we are committed to making a positive impact in their recovery journey.

To learn more, read our press release here: https://www.tensivemed.com/tensive-s-r-l-announces-multi-center-pivotal-clinical-trial-for-regenera-implant-in-post-lumpectomy-breast-reconstruction/


IEO Istituto Europeo di Oncologia

Tensive S.r.l. Announces Multi-Center Pivotal Clinical Trial for REGENERA Implant in Post-Lumpectomy Breast Reconstruction | Tensive Tensive S.r.l. announces the launch of a groundbreaking multi-center clinical trial that represents a significant advancement in the post-lumpectomy breast reconstruction field.